Press Releases

Roswell Park Comprehensive Cancer Center hematology experts from many disciplines and subspecialties were invited to present new research at the American Society of Hematology (ASH) 60th Annual Meeting, which begins today and continues through Tuesday, Dec. 4, in San Diego, California. The dozens of research projects they will highlight include new research on management of aggressive and rare lymphomas, approaches for optimizing cellular therapies such as blood and marrow transplant, and decision-making around genomic testing for patients with acute myeloid leukemia.

The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients. These new findings — including a molecular analysis detailing study participants’ levels of a key biomarker, MGMT — were presented earlier this month at the Society for Neuro-Oncology (SNO) Annual Meeting in New Orleans.

The latest results from an ongoing clinical study incorporating the immunotherapy SurVaxM as part of combination treatment for glioblastoma show that this investigational drug is safe, well-tolerated and extended survival even among the hardest-to-treat subgroups of patients. These new findings — including a molecular analysis detailing study participants’ levels of a key biomarker, MGMT — were presented Friday at the Society for Neuro-Oncology (SNO) Annual Meeting in New Orleans.

The Buffalo Sabres today announced the team, in partnership with Roswell Park Comprehensive Cancer Center, will again take part in the NHL’s Hockey Fights Cancer™ program during the team’s home game against the San Jose Sharks on Tuesday, Nov. 27, at 7 p.m.

In an effort to compile and summarize the latest knowledge about immunotherapy combinations and their implications, a group of kidney cancer immunotherapy experts led by Saby George, MD, of Roswell Park Comprehensive Cancer Center have written a new research review article assessing current approaches to treating patients newly diagnosed with kidney cancer and also looking ahead to some of the most pressing questions still to be answered related to these emerging therapies. Published by the journal JAMA Oncology, the review article highlights the path to approval for the new standard of care for these patients — ipilimumab, also known as Yervoy, together with nivolumab, also known as Opdivo.

Roswell Park has formed an academic cooperation agreement with the Jagiellonian University (JU) in Kraków, Poland. The collaboration will see the two centers exchanging staff, students and scientific resources to jointly undertake basic, translational and clinical research in order to advance the development of cancer therapies to benefit patients worldwide.

Roswell Park Comprehensive Cancer Center’s President and CEO, Candace S. Johnson, PhD, has been named to a new list of the most powerful female leaders in New York. City & State, a media company covering government and politics in New York, included Dr. Johnson on its New York Women’s Power 100 list, which honors the 100 most influential women in government, public affairs, business, culture and social services. Also named to this new list of distinguished New Yorkers is Leecia Eve, JD, who was recently appointed to the Roswell Park Board of Directors by Gov. Andrew Cuomo.

Roswell Park has again been named to Becker’s Hospital Review’s 100 Hospitals and Health Systems with Great Oncology Programs, an annual list of centers that are national leaders in patient care, cancer outcomes and research. Roswell Park is one of only six New York State centers to be included, and the only one in Western and Upstate New York.